Revised criteria for the myeloproliferative disorders: Too much too soon? [4]

Blood

Volumn 111, Issue 3, 2008, Pages 1741-

  Samuelson, Scott J ^a   Parker, Charles J ^b   Prchal, Josef T ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; VON HIPPEL LINDAU PROTEIN;

CRITERION VARIABLE; GENE MUTATION; HUMAN; LETTER; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; WORLD HEALTH ORGANIZATION;

EID: 38949169232     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-10-116897     Document Type: Letter

References (5)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
2. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol. 2005;130:153-165.
3. Hussein K, Bock O, Kreipe H. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Pathobiology. 2007;74:72-80.
4. Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol. 2005;42:266-273.
5. Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/ erythrocytoses. Haematologica. 2005;90:109-116.